Co-Authors
This is a "connection" page, showing publications co-authored by SETH LERNER and SURENA MATIN.
Connection Strength
2.201
-
Reply by Authors. J Urol. 2022 04; 207(4):788.
Score: 0.857
-
Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. J Urol. 2022 Apr; 207(4):779-788.
Score: 0.854
-
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020 06; 21(6):776-785.
Score: 0.191
-
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2017 10; 72(4):641-649.
Score: 0.156
-
Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. Eur Urol Oncol. 2021 04; 4(2):170-179.
Score: 0.050
-
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019 07 05; 10(1):2977.
Score: 0.045
-
Perioperative chemotherapy for upper tract urothelial cancer. Nat Rev Urol. 2012 Apr 10; 9(5):266-73.
Score: 0.027
-
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9.
Score: 0.020